Progyny, Inc.

NasdaqGS:PGNY Stock Report

Market Cap: US$2.0b

Progyny Management

Management criteria checks 4/4

Progyny's CEO is Pete Anevski, appointed in Jan 2022, has a tenure of 3.08 years. total yearly compensation is $1.09M, comprised of 45.7% salary and 54.3% bonuses, including company stock and options. directly owns 0.44% of the company’s shares, worth $8.64M. The average tenure of the management team and the board of directors is 3.1 years and 7.9 years respectively.

Key information

Pete Anevski

Chief executive officer

US$1.1m

Total compensation

CEO salary percentage45.7%
CEO tenure3.1yrs
CEO ownership0.4%
Management average tenure3.1yrs
Board average tenure7.9yrs

Recent management updates

Recent updates

Capital Allocation Trends At Progyny (NASDAQ:PGNY) Aren't Ideal

Jan 30
Capital Allocation Trends At Progyny (NASDAQ:PGNY) Aren't Ideal

Progyny: The Growth Story Remains Intact

Jan 15

Progyny, Inc.'s (NASDAQ:PGNY) P/E Is Still On The Mark Following 28% Share Price Bounce

Jan 12
Progyny, Inc.'s (NASDAQ:PGNY) P/E Is Still On The Mark Following 28% Share Price Bounce

Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)?

Jan 03
Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)?

The Bottom Fishing Club: Progyny Reverses On Heavy Insider Buying

Dec 31

Progyny: Rating Downgrade On Uncertain Growth Outlook

Nov 26

Progyny's (NASDAQ:PGNY) Solid Earnings Have Been Accounted For Conservatively

Nov 21
Progyny's (NASDAQ:PGNY) Solid Earnings Have Been Accounted For Conservatively

Progyny: After A Terrible Year, I'm Out (Rating Downgrade)

Nov 18

Here's What's Concerning About Progyny's (NASDAQ:PGNY) Returns On Capital

Oct 21
Here's What's Concerning About Progyny's (NASDAQ:PGNY) Returns On Capital

Progyny: Poor Year Raises Concerns For Future (Downgrade)

Oct 15

Progyny, Inc.'s (NASDAQ:PGNY) Stock Retreats 28% But Earnings Haven't Escaped The Attention Of Investors

Sep 29
Progyny, Inc.'s (NASDAQ:PGNY) Stock Retreats 28% But Earnings Haven't Escaped The Attention Of Investors

Progyny: Downgrading As Uncertainties Increase

Aug 15

Progyny, Inc. (NASDAQ:PGNY) Stocks Pounded By 25% But Not Lagging Market On Growth Or Pricing

Aug 11
Progyny, Inc. (NASDAQ:PGNY) Stocks Pounded By 25% But Not Lagging Market On Growth Or Pricing

At US$27.79, Is Progyny, Inc. (NASDAQ:PGNY) Worth Looking At Closely?

Jul 20
At US$27.79, Is Progyny, Inc. (NASDAQ:PGNY) Worth Looking At Closely?

Progyny: Recent Stock Decline Provides Buying Opportunity

Jul 12

Progyny's (NASDAQ:PGNY) Returns Have Hit A Wall

Jun 23
Progyny's (NASDAQ:PGNY) Returns Have Hit A Wall

Progyny: At This Price, Secular Tailwinds Are Too Compelling To Ignore

Jun 10

Progyny: No Change To Long-Term Outlook

Jun 04

Why We're Not Concerned About Progyny, Inc.'s (NASDAQ:PGNY) Share Price

Apr 29
Why We're Not Concerned About Progyny, Inc.'s (NASDAQ:PGNY) Share Price

Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)?

Apr 03
Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)?

Progyny: Long-Term Outlook Remains Positive, Reiterate Buy

Mar 15

Progyny: Long-Term Thesis Still Intact

Mar 09

Progyny's (NASDAQ:PGNY) Returns On Capital Are Heading Higher

Mar 01
Progyny's (NASDAQ:PGNY) Returns On Capital Are Heading Higher

Progyny, Inc.'s (NASDAQ:PGNY) P/E Still Appears To Be Reasonable

Jan 07
Progyny, Inc.'s (NASDAQ:PGNY) P/E Still Appears To Be Reasonable

Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?

Dec 11
Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?

Returns Are Gaining Momentum At Progyny (NASDAQ:PGNY)

Nov 08
Returns Are Gaining Momentum At Progyny (NASDAQ:PGNY)

Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?

Aug 24
Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?

There's Been No Shortage Of Growth Recently For Progyny's (NASDAQ:PGNY) Returns On Capital

Aug 06
There's Been No Shortage Of Growth Recently For Progyny's (NASDAQ:PGNY) Returns On Capital

Progyny (NASDAQ:PGNY) Is Looking To Continue Growing Its Returns On Capital

May 06
Progyny (NASDAQ:PGNY) Is Looking To Continue Growing Its Returns On Capital

CEO Compensation Analysis

How has Pete Anevski's remuneration changed compared to Progyny's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$57m

Jun 30 2024n/an/a

US$63m

Mar 31 2024n/an/a

US$61m

Dec 31 2023US$1mUS$500k

US$62m

Sep 30 2023n/an/a

US$52m

Jun 30 2023n/an/a

US$49m

Mar 31 2023n/an/a

US$43m

Dec 31 2022US$69mUS$500k

US$30m

Sep 30 2022n/an/a

US$42m

Jun 30 2022n/an/a

US$46m

Mar 31 2022n/an/a

US$56m

Dec 31 2021US$786kUS$425k

US$66m

Sep 30 2021n/an/a

US$90m

Jun 30 2021n/an/a

US$78m

Mar 31 2021n/an/a

US$58m

Dec 31 2020US$910kUS$425k

US$46m

Sep 30 2020n/an/a

US$3m

Jun 30 2020n/an/a

-US$10m

Mar 31 2020n/an/a

-US$5m

Dec 31 2019US$5mUS$375k

-US$9m

Sep 30 2019n/an/a

-US$6m

Jun 30 2019n/an/a

US$1m

Mar 31 2019n/an/a

-US$4m

Dec 31 2018US$682kUS$325k

-US$6m

Compensation vs Market: Pete's total compensation ($USD1.09M) is below average for companies of similar size in the US market ($USD5.31M).

Compensation vs Earnings: Pete's compensation has been consistent with company performance over the past year.

CEO

Pete Anevski (57 yo)

3.1yrs

Tenure

US$1,093,512

Compensation

Mr. Peter Anevski, also known as Pete, has been Chief Executive Officer and Director of Progyny, Inc. since January 2022 and had been its President since June 2019 until December 31, 2021 and was its Chief...

Leadership Team

NamePositionTenureCompensationOwnership
David Schlanger
Executive Chairman7.9yrsUS$513.57k0.24%
$ 4.8m
Peter Anevski
CEO & Director3.1yrsUS$1.09m0.44%
$ 8.6m
Michael Sturmer
President3.1yrsUS$1.49m0.087%
$ 1.7m
Mark Livingston
Chief Financial Officer4.4yrsUS$1.40m0.049%
$ 963.8k
Allison Swartz
Executive VP2.3yrsUS$546.22k0.022%
$ 440.8k
Steven Leist
Chief Technology Officer1.1yrsno datano data
James Hart
Vice President of Investor Relationsno datano datano data
Risa Fisher
Chief Marketing Officerno datano datano data
Cassandra Pratt
Chief Human Resources Officerno datano datano data
Julie Stadlbauer
Chief Business Development Officer3.1yrsno datano data
Janet Choi
Member of the Medical Advisory Board & Chief Medical Officer1.8yrsno datano data
Arielle Bogorad
Senior Vice President of Employer Market Strategy2.8yrsno datano data

3.1yrs

Average Tenure

57yo

Average Age

Experienced Management: PGNY's management team is considered experienced (3.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
David Schlanger
Executive Chairman7.9yrsUS$513.57k0.24%
$ 4.8m
Peter Anevski
CEO & Director3.1yrsUS$1.09m0.44%
$ 8.6m
Janet Choi
Member of the Medical Advisory Board & Chief Medical Officerno datano datano data
Norman Payson
Independent Director8.2yrsUS$567.30k0.48%
$ 9.4m
Fred Cohen
Independent Director9.9yrsUS$583.35k0.014%
$ 281.2k
Beth Seidenberg
Lead Independent Director14.8yrsUS$653.39k0.30%
$ 6.0m
Kevin Gordon
Independent Director5.3yrsUS$518.30k0.0073%
$ 143.6k
Jeffrey Park
Independent Director5.3yrsUS$606.88k0.014%
$ 281.2k
Alan Copperman
Member of the Medical Advisory Boardno datano datano data
Barry Behr
Member of Medical Advisory Boardno datano datano data
Brad Kolb
Member of Medical Advisory Boardno datano datano data
Gerard Letterie
Member of Medical Advisory Boardno datano datano data

7.9yrs

Average Tenure

65yo

Average Age

Experienced Board: PGNY's board of directors are considered experienced (7.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 02:22
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Progyny, Inc. is covered by 20 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhilin LongBerenberg
Nisala WeerasuriyaBerenberg
Allen LutzBofA Global Research